Puma Biotechnology Inc
pumabiotechnology.comPuma Biotechnology Inc (NASDAQ: PBYI) is a biopharmaceutical company that develops and commercializes drug candidates for the treatment of cancer. The company generates revenue from product sales of its approved oncology therapeutics. Puma Biotechnology trades on the NASDAQ Global Select Market, as disclosed in its 10-K filed February 26, 2026. The filing excerpts provided do not contain sufficient detail to specify segment revenue figures, key product names, customer concentration, geographic mix, founding year, current CEO tenure, or named competitors with support from the source document. Based solely on the available filing excerpts, the company is a small-cap biopharmaceutical issuer, with common stock carrying a closing price of $3.43 per share as of June 30, 2025, and is not classified as a well-known seasoned issuer under SEC Rule 405.
Products & Services
The filing excerpts do not name specific products or services with enough detail to summarize.
Revenue Model
The filing excerpts do not provide sufficient detail to describe the revenue model with specificity.
Customers & Markets
The filing excerpts do not provide customer or end market detail sufficient for description.
Geographic Exposure
The filing excerpts do not specify geographic revenue mix.
Loading...
